Berenberg initiated coverage of BioNTech (BNTX) with a Buy rating and $130 price target The firm says mRNA will revolutionize the treatment of multiple diseases. The analyst prefers BioNTech for exposure citing its “superior financial management and balance sheet, higher returns and oncology focus.” BioNTech’s shares trade below the value of its cash position and marketed COVID-19 business, the analyst tells investors in a research note.
Don't Miss out on Research Tools:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BNTX:
- Deutsche downgrades GSK to Hold on Trump’s RFK nomination
- Vaccine makers fall after Trump nominates RFK to head HHS
- Trump names Robert Kennedy as Secretary of Health and Human Services
- BioNTech SE’s Strategic Growth in Oncology and mRNA
- BioNTech Acquires Biotheus to Enhance Cancer Therapies
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
